JP4454151B2 - 大環状類似体及びそれらの使用並びに調製方法 - Google Patents

大環状類似体及びそれらの使用並びに調製方法 Download PDF

Info

Publication number
JP4454151B2
JP4454151B2 JP2000554719A JP2000554719A JP4454151B2 JP 4454151 B2 JP4454151 B2 JP 4454151B2 JP 2000554719 A JP2000554719 A JP 2000554719A JP 2000554719 A JP2000554719 A JP 2000554719A JP 4454151 B2 JP4454151 B2 JP 4454151B2
Authority
JP
Japan
Prior art keywords
mmol
added
etoac
compound
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000554719A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002518384A (ja
JP2002518384A5 (enExample
Inventor
リトルフィールド，ブルース，エイ
パルメ，モニカ
セレトスキー，ボリス，エム
トウル，マレイ，ジェイ
ユー，メルビン，ジェイ
ツェン，ワンジュン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22219026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4454151(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2002518384A publication Critical patent/JP2002518384A/ja
Publication of JP2002518384A5 publication Critical patent/JP2002518384A5/ja
Application granted granted Critical
Publication of JP4454151B2 publication Critical patent/JP4454151B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2000554719A 1998-06-17 1999-06-16 大環状類似体及びそれらの使用並びに調製方法 Expired - Lifetime JP4454151B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8968298P 1998-06-17 1998-06-17
US60/089,682 1998-06-17
PCT/US1999/013677 WO1999065894A1 (en) 1998-06-17 1999-06-16 Macrocyclic analogs and methods of their use and preparation

Publications (3)

Publication Number Publication Date
JP2002518384A JP2002518384A (ja) 2002-06-25
JP2002518384A5 JP2002518384A5 (enExample) 2009-10-01
JP4454151B2 true JP4454151B2 (ja) 2010-04-21

Family

ID=22219026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000554719A Expired - Lifetime JP4454151B2 (ja) 1998-06-17 1999-06-16 大環状類似体及びそれらの使用並びに調製方法

Country Status (22)

Country Link
US (4) US6214865B1 (enExample)
EP (4) EP2272839B1 (enExample)
JP (1) JP4454151B2 (enExample)
KR (1) KR100798600B1 (enExample)
CN (1) CN1216051C (enExample)
AT (1) ATE502932T1 (enExample)
AU (1) AU762998B2 (enExample)
BE (1) BE2011C028I2 (enExample)
BR (1) BRPI9911326B8 (enExample)
CA (3) CA2632433C (enExample)
CY (2) CY1111516T1 (enExample)
DE (2) DE122011100031I1 (enExample)
DK (1) DK1087960T3 (enExample)
FR (1) FR11C0038I2 (enExample)
HU (1) HU227912B1 (enExample)
IL (1) IL139960A0 (enExample)
LU (1) LU91854I2 (enExample)
NO (5) NO328280B1 (enExample)
NZ (1) NZ508597A (enExample)
PT (1) PT1087960E (enExample)
WO (1) WO1999065894A1 (enExample)
ZA (1) ZA200007159B (enExample)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2632433C (en) * 1998-06-17 2012-02-07 Eisai R & D Management Co., Ltd. Methods for preparing macrocyclic analogs and intermediates for preparing same
US8097648B2 (en) * 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
WO2003072754A2 (en) * 2002-02-27 2003-09-04 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
WO2003082268A2 (en) 2002-03-22 2003-10-09 Eisai Co. Ltd Hemiasterlin derivatives and uses thereof in the treatment of cancer
US20050075395A1 (en) * 2003-05-28 2005-04-07 Gary Gordon Continuous dosing regimen
CA2526385C (en) * 2003-05-29 2008-07-22 Abbott Laboratories Continuous dosing regimen with abt-751
WO2005011589A2 (en) * 2003-07-29 2005-02-10 Eisai Co., Ltd. Drug delivery methods and devices
KR101434673B1 (ko) * 2004-06-03 2014-08-26 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 ｂ 유사체의 제조를 위한 중간체
CN108997267A (zh) * 2004-06-03 2018-12-14 卫材R&D管理有限公司 用于制备软海绵素b的类似物的中间体
US20060045846A1 (en) * 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
JP2008522623A (ja) * 2004-12-09 2008-07-03 エーザイ株式会社 ハリコンドリンｂアナログを使用した癌治療でのチューブリンアイソタイプのスクリーニング
EP2578576B9 (en) * 2007-10-03 2016-09-14 Eisai R&D Management Co., Ltd. Intermediates for the synthesis of halichondrin B analogs
RU2517167C2 (ru) * 2008-04-04 2014-05-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Аналоги галихондрина в
PE20120923A1 (es) 2009-03-30 2012-08-27 Eisai Randd Man Co Ltd Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismo
RU2476216C1 (ru) * 2009-03-30 2013-02-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Липосомальная композиция
WO2010113983A1 (ja) 2009-03-30 2010-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物の製造方法
WO2010119890A1 (ja) * 2009-04-14 2010-10-21 日産化学工業株式会社 テトラヒドロピラン化合物の製造方法およびその中間体
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
US8203010B2 (en) 2010-01-26 2012-06-19 Eisai R&D Management Co., Ltd. Compounds useful in the synthesis of halichondrin B analogs
EP2686441B1 (en) 2011-03-18 2019-05-08 Eisai R&D Management Co., Ltd. Methods and uses for predicting response to eribulin
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
CA2857385A1 (en) 2011-11-30 2013-06-06 Alphora Research Inc. Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
JP2015501818A (ja) 2011-12-16 2015-01-19 アルフォラ リサーチ インコーポレイテッドＡｌｐｈｏｒａ Ｒｅｓｅａｒｃｈ Ｉｎｃ． ３−（（２ｓ，５ｓ）−４−メチレン−５−（３−オキソプロピル）テトラヒドロフラン−２−イル）プロパノール誘導体およびそれらの有用な中間体を調製する方法
IN2014MN01521A (enExample) * 2011-12-29 2015-05-01 Alphora Res Inc
CN104334562A (zh) * 2012-03-30 2015-02-04 阿方拉研究股份有限公司 用于制备软海绵素b的大环c1-酮类似物的合成方法及其中有用的中间体
AU2013353745A1 (en) 2012-12-04 2015-06-11 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer
US9650397B2 (en) 2013-05-15 2017-05-16 Alphora Research Inc. 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof
CN105338977B (zh) 2013-06-26 2018-10-16 卫材R&D管理有限公司 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
WO2015000070A1 (en) 2013-07-03 2015-01-08 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
CN103483352A (zh) * 2013-10-18 2014-01-01 李友香 抗肿瘤的药用原料药
CA2929084C (en) 2013-11-04 2022-01-11 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin b
BR112016012237B1 (pt) 2013-12-06 2023-02-07 Eisai R&D Management Co., Ltd Métodos úteis na síntese de análogos de halicondrina b
CN104860978A (zh) * 2014-02-20 2015-08-26 正大天晴药业集团股份有限公司 软海绵素b类似物的合成中间体
TW201617326A (zh) 2014-03-06 2016-05-16 Ａｌｐｈｏｒａ研發股份有限公司 （ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物
WO2015183961A1 (en) 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd Use of eribulin in the treatment of cancer
WO2016003975A1 (en) 2014-06-30 2016-01-07 President And Fellows Of Harvard College Synthesis of halichondrin analogs and uses thereof
EP3187491A4 (en) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US10208058B2 (en) 2014-09-09 2019-02-19 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts and intermediates thereof
CN105713031B (zh) * 2014-12-05 2021-05-07 正大天晴药业集团股份有限公司 一种用于制备艾日布林的中间体及其制备方法
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
MX386547B (es) * 2015-03-04 2025-03-19 Merck Sharp & Dohme Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer.
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
WO2016176560A1 (en) 2015-04-30 2016-11-03 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
MX392296B (es) * 2015-05-07 2025-03-24 Eisai R&D Man Co Ltd Reacciones de macrociclizacion e intermediarios y otros fragmentos utiles en la sintesis de macrolidos de halicondrina.
US10597401B2 (en) 2015-05-08 2020-03-24 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
MX377663B (es) 2016-02-12 2025-03-11 Eisai R&D Man Co Ltd Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados.
WO2017188350A1 (ja) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
CN109415383A (zh) * 2016-05-26 2019-03-01 雷迪博士实验室有限公司 制备艾日布林的方法及其中间体
US11136335B2 (en) 2016-06-30 2021-10-05 Eisai R&D Management Co., Ltd. Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
SG11201902974PA (en) 2016-10-14 2019-05-30 Merck Sharp & Dohme Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
BR112019010494A2 (pt) * 2016-11-23 2019-09-17 Dr Reddys Laboratories Ltd processo para a preparação de eribulina e intermediários do mesmo
KR101991710B1 (ko) 2017-12-14 2019-06-21 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
KR101880939B1 (ko) 2017-01-02 2018-08-17 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
CN110139866B (zh) * 2017-01-02 2022-05-17 研成精密化学株式会社 用于制备甲磺酸艾日布林的中间体以及制备其的方法
CN108341738B (zh) * 2017-01-24 2022-10-21 江苏恒瑞医药股份有限公司 用于制备艾日布林的方法及其中间体
CN108341828B (zh) * 2017-01-24 2021-04-06 江苏恒瑞医药股份有限公司 用于制备艾日布林的方法及其中间体
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
SI3606928T1 (sl) 2017-04-05 2023-02-28 President And Fellows Of Harvard College Makrociklična spojina in njene uporabe
WO2018212202A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
HUE061306T2 (hu) 2017-07-06 2023-06-28 Harvard College Halikondrinok szintézise
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
US20190046513A1 (en) 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
CN109694379B (zh) * 2017-10-24 2020-09-11 江苏恒瑞医药股份有限公司 用于制备艾日布林的中间体及其制备方法
WO2019093776A1 (ko) 2017-11-09 2019-05-16 연성정밀화학(주) 에리불린 메실산염의 제조 중간체 및 그의 제조방법
CN111566113B (zh) 2017-11-15 2024-01-09 哈佛大学的校长及成员们 大环化合物及其用途
EP3713565A1 (en) 2017-11-20 2020-09-30 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
US11008296B2 (en) 2017-11-21 2021-05-18 Natco Pharma Limited Intermediates for the preparation of eribulin thereof
MX2020006945A (es) 2018-01-03 2020-11-09 Eisai R&D Man Co Ltd Reaccion de prins y compuestos utiles en la sintesis de macrolidos de halicondrina y analogos de los mismos.
WO2019211877A1 (en) 2018-05-03 2019-11-07 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin b
WO2020008382A1 (en) * 2018-07-04 2020-01-09 Dr. Reddy’S Laboratories Limited Process for preparation of eribulin and intermediates thereof
CN112437775A (zh) * 2018-07-20 2021-03-02 雷迪博士实验室有限公司 用于制备艾日布林及其中间体的纯化方法
WO2020075027A1 (en) * 2018-10-09 2020-04-16 Dr. Reddy's Laboratories Limited Process for preparation of eribulin and intermediates thereof
WO2020110146A1 (en) * 2018-11-28 2020-06-04 Natco Pharma Limited Process for the preparation of high pure eribulin and its mesylate salt
CN113766914B (zh) 2018-12-20 2024-02-13 美商奥润沙公司 戊烷脒的类似物和其用途
US11447499B2 (en) 2019-06-14 2022-09-20 Rk Pharma Inc. Process for the preparation of eribulin mesylate intermediate
US12247239B2 (en) 2019-06-21 2025-03-11 Council Of Scientific & Industrial Research Chemo-enzymatic process for the preparation of homopropargylic alcohol
ES3075649T3 (en) 2019-07-26 2026-08-06 Eisai R&D Man Co Ltd Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
WO2021090062A1 (en) 2019-11-07 2021-05-14 Eisai R&D Management Co., Ltd. Anti-mesothelin eribulin antibody-drug conjugates and methods of use
CN113135876B (zh) * 2020-01-16 2024-05-17 南通诺泰生物医药技术有限公司 艾日布林及其中间体的制备方法
JP7821733B2 (ja) * 2020-01-22 2026-02-27 上海森輝医薬有限公司 エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用
KR102377262B1 (ko) 2020-05-11 2022-03-22 연성정밀화학(주) 결정성 에리불린 염
IL279168B (en) 2020-12-02 2022-04-01 Finetech Pharmaceutical Ltd A process for the preparation of eribulin
CN113354659B (zh) 2021-06-08 2022-04-08 江苏慧聚药业股份有限公司 甲磺酸艾日布林的合成
MX2024000893A (es) * 2021-07-22 2024-02-06 Shanghai Senhui Medicine Co Ltd Farmaco conjugado de un derivado de eribulina.
WO2023212746A2 (en) * 2022-04-30 2023-11-02 William Marsh Rice University A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b
AU2024209545A1 (en) * 2023-01-17 2025-08-07 Systimmune, Inc. Conjugate of eribulin drug
EP4725969A1 (en) 2023-06-09 2026-04-15 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Anti-her2 complementary bispecific antibody-drug conjugate, preparation method therefor and use thereof
CN118834221B (zh) * 2023-08-08 2025-10-21 浙江星月药物科技有限公司 一种软海绵素b类似物
CN122349614A (zh) 2023-10-13 2026-07-07 卫材R&D管理有限公司 抗体-药物缀合物代谢物
WO2025106586A1 (en) * 2023-11-13 2025-05-22 Luxvitae Therapeutics Inc. Macrocyclic ketone compounds and applications thereof
WO2025228172A1 (zh) * 2024-04-28 2025-11-06 上海拓济医药有限责任公司 艾日布林衍生物及其抗体药物偶联物和医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338865A (en) * 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
GB9206244D0 (en) * 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
US5426194A (en) * 1993-01-19 1995-06-20 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Isolation and structure of Halistatin 1
CA2632433C (en) * 1998-06-17 2012-02-07 Eisai R & D Management Co., Ltd. Methods for preparing macrocyclic analogs and intermediates for preparing same
US6653341B1 (en) * 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
KR101434673B1 (ko) 2004-06-03 2014-08-26 에자이 알앤드디 매니지먼트 가부시키가이샤 할리콘드린 ｂ 유사체의 제조를 위한 중간체
EP2578576B9 (en) * 2007-10-03 2016-09-14 Eisai R&D Management Co., Ltd. Intermediates for the synthesis of halichondrin B analogs
CN101910180A (zh) * 2007-11-16 2010-12-08 卫材R&D管理有限公司 用于软海绵素b类似物合成的新颖中间体和用于该中间体的新颖脱磺酰化反应
RU2517167C2 (ru) * 2008-04-04 2014-05-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Аналоги галихондрина в
US8203010B2 (en) * 2010-01-26 2012-06-19 Eisai R&D Management Co., Ltd. Compounds useful in the synthesis of halichondrin B analogs

Also Published As

Publication number Publication date
KR20010083050A (ko) 2001-08-31
WO1999065894A1 (en) 1999-12-23
US8148554B2 (en) 2012-04-03
US6365759B1 (en) 2002-04-02
EP2272839A1 (en) 2011-01-12
DK1087960T3 (da) 2011-06-14
NO20093217L (no) 2001-02-15
CA2335300C (en) 2008-10-07
HU227912B1 (en) 2012-05-29
CA2755266A1 (en) 1999-12-23
ZA200007159B (en) 2001-12-04
NO20006316D0 (no) 2000-12-12
NO2022019I1 (no) 2022-06-03
CA2632433A1 (en) 1999-12-23
NZ508597A (en) 2004-01-30
BE2011C028I2 (en) 2018-08-24
ATE502932T1 (de) 2011-04-15
US6469182B1 (en) 2002-10-22
JP2002518384A (ja) 2002-06-25
NO2011026I2 (no) 2012-06-11
NO331183B1 (no) 2011-10-24
EP2272840A1 (en) 2011-01-12
HUP0103357A3 (en) 2002-10-28
LU91854I2 (fr) 2011-10-17
RU2245335C2 (ru) 2005-01-27
NO2011026I1 (no) 2012-01-09
PT1087960E (pt) 2011-06-17
FR11C0038I2 (fr) 2013-01-11
AU4573999A (en) 2000-01-05
CN1216051C (zh) 2005-08-24
HK1035534A1 (en) 2001-11-30
EP2277873B1 (en) 2012-05-30
BR9911326A (pt) 2001-04-03
US6214865B1 (en) 2001-04-10
KR100798600B1 (ko) 2008-01-28
AU762998C (en) 2000-01-05
EP2277873A1 (en) 2011-01-26
IL139960A0 (en) 2002-02-10
CA2335300A1 (en) 1999-12-23
NO328280B1 (no) 2010-01-25
DE69943296D1 (de) 2011-05-05
HUP0103357A2 (hu) 2002-01-28
BRPI9911326B8 (pt) 2021-05-25
CN1312804A (zh) 2001-09-12
BR9911326B1 (pt) 2015-01-06
EP2272839B1 (en) 2012-08-22
NO2011018I1 (no) 2011-09-26
DE122011100031I1 (de) 2011-12-15
EP2272840B1 (en) 2012-08-22
CY1111516T1 (el) 2014-04-09
NO20006316L (no) 2001-02-15
CA2632433C (en) 2012-02-07
EP1087960A4 (en) 2004-12-01
EP1087960A1 (en) 2001-04-04
CY2011010I2 (el) 2014-04-09
EP1087960B1 (en) 2011-03-23
US20110172446A1 (en) 2011-07-14
AU762998B2 (en) 2003-07-10
CA2755266C (en) 2014-08-12
CY2011010I1 (el) 2014-04-09
FR11C0038I1 (fr) 2011-10-14

Similar Documents

Publication Publication Date Title
JP2002518384A (ja) 大環状類似体及びそれらの使用並びに調製方法
JP4579351B2 (ja) エポチロンの合成とその中間体及びその類似物並びにその使用
RU2112773C1 (ru) Производные галихондрина b, производные конденсированных пиранов (варианты), производные гидрированного фурана, производные гидрированного пирана, производные енона галихондрина b, производные енона норгалихондрина
US5436238A (en) Halichondrins and related compounds
AU784589B2 (en) Bryostatin analogues, synthetic methods and uses
US20030220334A1 (en) Byrostatin analogues, synthetic methods and uses
PL189311B1 (pl) Nowe taksoidy, sposób ich wytwarzania i kompozycje farmaceutyczne zawierające te związki
Yu et al. Total Synthesis of (10 R)-and (10 S)-Corossolin: Determination of the Stereochemistry at C-10 of the Natural Corossolin and the Differential Toxicity toward Cancer Cells Caused by the Configuration at C-10
JP2003261447A (ja) 抗腫瘍剤
ES2364696T3 (es) Análogos macrocíclicos y procedimientos para su uso y preparación.
RU2822750C2 (ru) Микроциклические аналоги и способы их применения и получения
HK1035534B (en) Macrocyclic analogs and methods of their use and preparation
MXPA00012534A (en) Macrocyclic analogs and methods of their use and preparation
Glass Toward the total synthesis of taxol and its analogs
Rawlins Strategies for the synthesis of taxol and taxol analogs: 1. versatile intermediates to taxanes arising from methoxy-aromatic C-ring precursors. 2. A short synthesis of the oxetane D-ring
LT et al. DIOXASPIROKETALDERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND ANWENDUNGEN DAVON DÉRIVÉS DE DIOXASPIROCÉTAL, PROCÉDÉ DE PRÉPARATION ET UTILISATIONS DE CES DÉRIVÉS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060609

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20080310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090729

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20090729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090812

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20090818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100202

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100202

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130212

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4454151

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130212

Year of fee payment: 3

S202 Request for registration of non-exclusive licence

Free format text: JAPANESE INTERMEDIATE CODE: R315201

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130212

Year of fee payment: 3

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130212

Year of fee payment: 3

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130212

Year of fee payment: 3

S202 Request for registration of non-exclusive licence

Free format text: JAPANESE INTERMEDIATE CODE: R315201

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130212

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130212

Year of fee payment: 3

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130212

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140212

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term